27-Mar-2024
No headlines found.
Agenus Reports Fourth Quarter and Full Year 2023 Results
Business Wire (Thu, 14-Mar 7:30 AM ET)
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
Business Wire (Wed, 6-Mar 7:30 AM ET)
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Tue, 5-Mar 4:30 PM ET)
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
Business Wire (Thu, 29-Feb 7:30 AM ET)
Agenus to Participate in Leerink Partners Global Biopharma Conference
Business Wire (Mon, 26-Feb 7:30 AM ET)
PRNewswire (Thu, 15-Feb 7:02 AM ET)
Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
Business Wire (Wed, 31-Jan 7:30 AM ET)
Business Wire (Mon, 22-Jan 7:30 AM ET)
Agenus to Participate in B. Riley Healthcare Conference
Business Wire (Thu, 4-Jan 7:30 AM ET)
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Agenus trades on the NASDAQ stock market under the symbol AGEN.
As of March 27, 2024, AGEN stock price climbed to $0.56 with 3,457,542 million shares trading.
AGEN has a beta of 1.35, meaning it tends to be more sensitive to market movements. AGEN has a correlation of 0.04 to the broad based SPY ETF.
AGEN has a market cap of $233.09 million. This is considered a Small Cap stock.
Last quarter Agenus reported $84 million in Revenue and -$2.60 earnings per share. This beat revenue expectation by $37 million and missed earnings estimates by -$1.60.
In the last 3 years, AGEN stock traded as high as $6.79 and as low as $.49.
The top ETF exchange traded funds that AGEN belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
AGEN has underperformed the market in the last year with a price return of -62.7% while the SPY ETF gained +33.9%. AGEN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -32.2% and -16.9%, respectively, while the SPY returned +10.3% and +1.5%, respectively.
AGEN support price is $.50 and resistance is $.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGEN stock will trade within this expected range on the day.